abs249.txt	cabozantinib	is	a	multikinase	inhibitor	approved	for	the	treatment	of	metastaticmedullary	thyroid	cancer	and	advanced	renal	cell	carcinoma	(rcc)	in	patients	whohave	received	prior	anti-angiogenic	therapy		while	associations	between	serumcreatine	kinase	(ck)	elevations	and	other	tyrosine	kinase	inhibitors	used	for	thetreatment	of	solid	malignancies	have	been	previously	reported		we	report	a	caseof	cabozantinib-associated	ck	elevation	that	was	associated	with	musculoskeletalcomplaints	by	an	rcc	patient		nine	days	following	initiation	of	cabozantinib		thepatient	reported	muscle	cramps	and	serum	ck	had	increased	from	levels	12	monthsearlier	that	were	within	normal	limits	to	a	grade	1	elevation	of	244	units/l	despite	a	dose	reduction		her	ck	continued	to	rise	over	the	next	2	months	leading	to	a	peak	ck	of	914	units/l		due	to	this	grade	3	elevation		cabozantinibwas	permanently	discontinued		and	her	ck	subsequently	returned	to	a	grade	1elevation	within	one	week	and	then	to	baseline	within	3	weeks		the	temporalrelationship	between	drug	exposure	and	ck	increase	strongly	suggests	causality	to	the	authors'	knowledge		this	is	the	first	reported	case	of	ck	elevationattributed	to	cabozantinib		but	cabozantinib-induced	ck	elevations	could	beunder-reported		and	providers	should	monitor	for	musculoskeletal	complaintsduring	cabozantinib	therapy	
